Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A novel dry powder inhaler device will be used to administer mannitol to healthy subjects and subjects with bronchiectasis in single doses higher than previously given.The main objective is to assess tolerability of these doses using the new device.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| single | Experimental | single arm, open label, 4 doses tested. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| dry powder inhaled mannitol | Drug | single doses of 40 mg, 70 mg and 100 mg |
|
| Measure | Description | Time Frame |
|---|---|---|
| tolerability | immediately and 10 mins post dose |
| Measure | Description | Time Frame |
|---|---|---|
| respiratory symptoms, FEV1 | pre-dose, immediately and 10 mins post dose |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal Prince Alfred Hospital | Sydney | Australia |
Not provided
| ID | Term |
|---|---|
| D001987 | Bronchiectasis |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided